Greenlight Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Greenlight Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$2.8M	Buy	+268,470	New	+$2.51M	0.14%	31

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Greenlight Capital's TEVA Position: Q4 2023 in Review

Greenlight Capital opened a new position in Teva Pharmaceuticals (TEVA) in Q4 2023: 268,470 shares worth $2.8M. The stake represents 0.14% of the portfolio and ranks #31 among its holdings.

447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

Greenlight Capital held 268,470 shares of Teva Pharmaceuticals worth $2.8M as of Q4 2023.
Teva Pharmaceuticals was a new Greenlight Capital position in Q4 2023.
Teva Pharmaceuticals made up 0.14% of Greenlight Capital's portfolio in Q4 2023, its #31 holding.
447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on Greenlight Capital's 13F filing for Q4 2023, filed 14 Feb 2024.